Mark DeLong - Jun 16, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol
APLS
Transactions as of
Jun 16, 2022
Transactions value $
-$279,350
Form type
4
Date filed
6/21/2022, 04:11 PM
Previous filing
Apr 22, 2022
Next filing
Jul 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $139K +10K +34.19% $13.85 39.3K Jun 16, 2022 Direct
transaction APLS Common Stock Sale -$418K -10K -25.48% $41.79 29.3K Jun 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -10K -33.33% $0.00 20K Jun 16, 2022 Common Stock 10K $13.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This includes 769 shares from 4/30/22 ESPP purchase
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.